Ceritinib (Zykadia®) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC).
It is only used if tests show the cancer cells have a gene change, also called a gene mutation. This change affects a gene called anaplastic lymphoma kinase (ALK). NSCLC that has this gene change is called ALK-positive NSCLC.
It is best to read this information with our general information about targeted therapies and the type of cancer you have.
Your doctor will talk to you about this treatment and its possible side effects before you agree (consent) to have treatment.